Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program

TUCSON, Ariz., July 15, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC (“SynCardia”), maker of the world's first and only total artificial heart approved by the U.S. Food and Drug Administration (“FDA”) and Health Canada, today announced the publication of an independent commentary in Artificial Organs examining the Company's next-generation Emperor platform, which combines the Emperor Drive with the SynCardia Total Artificial Heart (“STAH”), and its role in the continued evolution of mechanical heart replacement technology.